All scale scores reduced significantly by week 2 of treatment and symptom

improvement became prominent at week 24. This finding is in line with literature data suggesting that amisulpride is effective in the control of both selleck positive and negative symptoms [Mortimer, 2009]. Early clinical response to amisulpride was observed at the second week of treatment in our study and this finding is in line with the meta-analysis of Agid and colleagues, who showed that a larger reduction of symptoms occurs during the first two weeks than during Inhibitors,research,lifescience,medical the second two weeks of amisulpride treatment [Agid et al. 2003]. Leucht and colleagues stated that clinical response to amisulpride showed the same time course pattern as that of the other antipsychotic drugs [Leucht et al. 2005]. The low incidence of extrapyramidal side effects assessed by SAS Inhibitors,research,lifescience,medical scores is in line with the findings of comparative trials [Carrière et al. 2000; Sechter et al. 2002; Mortimer et al. 2004]. It has been shown in animal studies [Schoemaker et al. 1997] and also in humans [Bressan et al. 2003] that amisulpride

has selectivity for mesolimbic over striatal dopamine mechanisms. This selectivity probably explains why, similarly Inhibitors,research,lifescience,medical to other SGAs, amisulpride induces fewer extrapyramidal side effects. Recently, much attention has been focused on the increased metabolic syndrome components among patients receiving antipsychotics, including weight gain, glucose intolerance, hyperglycemia, diabetes mellitus, hyperlipidemia and hypertension Inhibitors,research,lifescience,medical [Kabinoff et al. 2003]. In our study, mean values for BMI did not differ between baseline and endpoint. Amisulpride is associated with only a slight weight gain of approximately 0.8 kg within 24 weeks. This is comparable with the data of Leucht and colleagues who stated that mean weight

gain with amisulpride (doses above 400 mg/day) is Inhibitors,research,lifescience,medical 1.27 kg in 6 months [Leucht et al. 2004]. Amisulpride is associated with little effect on weight gain in a recent meta-analysis [Leucht et al. 2009]. A review by Taylor and McAskill ranking atypical antipsychotic drugs according to their associated risk of weight gain, recorded the lowest risk with amisulpride [Taylor and McAskill, 2000]. There GSK-3 are very few data available on the other metabolic effects of amisulpride. Consensus guidelines, published in Belgium, on metabolic problems with atypical antipsychotics recommended that atypical antipsychotics with the lowest risk profile (amisulpride, aripiprazole and ziprasidone) be preferred, particularly in patients with other identified risk factors for metabolic complications [De Hert et al. 2006]. Peuskens and colleagues such information reported lower risk of weight gain and hyperglycemia associated with amisulpride treatment compared with olanzapine [Peuskens et al. 2007].